Transferases (2. ), Lyase (4.), Isomerase (5.), Ligase (6.) Patents (Class 424/94.5)
  • Patent number: 10865403
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cancer and cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 15, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Shira Cramer
  • Patent number: 10865419
    Abstract: Disclosed herein are compositions and methods for treating Type II diabetes. The compositions comprise plant expressed Exendin 4. Particularly exemplified are plant derived compositions that include a CTB-EX4 conjugate that is bioencapsulated in chloroplasts.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: December 15, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Henry Daniell
  • Patent number: 10857130
    Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: December 8, 2020
    Assignee: UNM Rainforest Innovations
    Inventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
  • Patent number: 10736944
    Abstract: The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis-derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis-derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: August 11, 2020
    Assignee: KONKUK UNIVERSITY GLOCAL INDUSTRY-ACADEMIC COLLABORATION FOUNDATION
    Inventors: Yeong Min Park, In Duk Jung, Sung Jae Shin, Jung Hee Park, Seung Jun Lee, Tae Heung Kang, Byoung Yul Soh
  • Patent number: 10655135
    Abstract: Disclosed herein are compositions and methods for treating Type II diabetes. The compositions comprise plant expressed Exendin 4. Particularly exemplified are plant derived compositions that include a CTB-EX4 conjugate that is bioencapsulated in chloroplasts.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: May 19, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Henry Daniell
  • Patent number: 10653782
    Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients). In some embodiments, provided herein are therapeutic devices comprising: (a) a vector encoding Sirtuin-1 (Sirt 1); and (b) a hydrogel carrier. In some embodiments, the vector comprises a viral vector comprising a polynucleotide sequence encoding Sirt 1. In some embodiments, the vector comprises a non-viral vector comprising a polynucleotide sequence encoding Sirt1.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 19, 2020
    Assignee: Nortwestern University
    Inventors: Guillermo A. Ameer, Michele Jen
  • Patent number: 10646547
    Abstract: A polypeptide having chemokine activity mediated by binding to C-C chemokine receptor type 3 (CCR3) comprising SEQ ID NO: 1 and uses thereof are described.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: May 12, 2020
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Min Chul Park, Byung Woo Han, Joon-Sung Park
  • Patent number: 10607716
    Abstract: Methods for design of genetic circuits are provided.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: March 31, 2020
    Assignee: The Regents of the University of California
    Inventors: Chunbo Lou, Tae Seok Moon, Virgil Rhodius, Brynne Stanton, Alvin Tamsir, Karsten Temme, Chris Voigt
  • Patent number: 10584318
    Abstract: Disclosed herein are compositions and formulations containing a TATk-CDKL5 fusion protein. Also disclosed are methods of producing a TATk-CDKL5 fusion protein from vectors containing a TATk-CDKL5 cDNA and methods of transducing cells with the vectors containing a TATk-CDKL5 cDNA and the TATk-CDKL5 fusion protein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: March 10, 2020
    Assignee: Alma Mater Studiorum—Università di Bologna
    Inventors: Elisabetta Ciani, Franco Laccone
  • Patent number: 10570468
    Abstract: Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 25, 2020
    Assignee: Allena Pharmaceuticals, Inc.
    Inventors: Jack Greene, Richard Johnson, Dennis Krushinskie, Bhami Shenoy
  • Patent number: 10507211
    Abstract: A method of treating demyelinating diseases involves administering a PAK1 inhibitor that is PF-3758309 to a subject in need of such treatment.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: December 17, 2019
    Assignees: Vanderbilt University, The United States as represented by the Department of Veterans Affairs
    Inventors: Jun Li, Bo Hu
  • Patent number: 10286045
    Abstract: Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided.
    Type: Grant
    Filed: April 21, 2018
    Date of Patent: May 14, 2019
    Assignee: KINETIQ, INC.
    Inventors: Mingju Cao, Alexander M. Cao
  • Patent number: 10280415
    Abstract: Human cystathionine ?-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine ?-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologs are described. In addition, a method to express and purify recombinant human cystathionine ?-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 7, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Jan P. Kraus
  • Patent number: 10246755
    Abstract: Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 2, 2019
    Assignee: Allena Pharmaceuticals, Inc.
    Inventors: Jack Greene, Richard Johnson, Dennis Krushinskie, Bhami Shenoy
  • Patent number: 10220077
    Abstract: A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: March 5, 2019
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventor: Daniel Offen
  • Patent number: 10131885
    Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 20, 2018
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric Ostertag, Blair Madison
  • Patent number: 10087435
    Abstract: The invention includes, in part, methods and compounds for treating diseases and conditions characterized by elevated threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is elevated as compared to normal. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess a treatment for a disease or condition characterized by elevated TARS activity.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: October 2, 2018
    Assignee: University of Vermont and State Agricultural College
    Inventors: Christopher Francklyn, Karen M. Lounsbury, Jason Botten
  • Patent number: 9987340
    Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 5, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Andrea Vecchione, Jennifer Iaci
  • Patent number: 9982243
    Abstract: Disclosed herein are a modified sulfamidase, a composition comprising a modified sulfamidase, as well as methods for preparing a modified sulfamidase and therapeutic use of such a sulfamidase. In particular, the present disclosure relates to a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: May 29, 2018
    Assignee: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Inventors: Charlotta Berghard, Erik Nordling, Stefan Svensson Gelius, Agneta Tjernberg
  • Patent number: 9902962
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques. The invention provides a chimeric polypeptide. The polypeptide includes: a) a recombinase, nuclease or transcription factor, or fragment thereof; and b) a transcription activator-like effector (TALE) protein.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: February 27, 2018
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Patent number: 9879320
    Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: January 30, 2018
    Inventors: Ivan Bieche, Bénédicte Watelet, Tarik Asselah, Isabelle Catherine Batxelli, Eve Laure Mathieu, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Mohammad Afshar
  • Patent number: 9846159
    Abstract: Provided are methods for screening a subject for cancer. The methods involve obtaining a blood sample from the subject and determining a level of Bridging Integrator 1 (BIN1) isoforms comprising exon 12a in the sample. Optionally, the method involves determining a level of 12a+/13? BIN isoform (comprising exon 12a but lacking exon 13) in the sample. An elevated level of 12a+ (e.g., 12a+/13?) BIN1 isoforms in the blood sample indicates the subject has cancer. Also provided are methods for determining efficacy of a cancer therapy in a subject and methods of treating cancer. Isolated antibodies that selectively bind human 12a+ BIN1 are also provided as well as kits for determining 12a+/13? BIN1 isoforms.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: December 19, 2017
    Assignee: Sarcotein Diagnostics, LLC
    Inventors: Darryl Steven Shaw, Neil Gavin Shaw
  • Patent number: 9840696
    Abstract: The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transposon, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 12, 2017
    Assignee: Max-Delbruck-Centrum Fur Molekulare Medizin
    Inventors: Zsuzsanna Izsvak, Zoltan Ivics, Lajos Mates, Namitha Manoj, Carmen-Anisia Judis, Andrea Katzer
  • Patent number: 9834764
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: December 5, 2017
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Hunter
  • Patent number: 9770500
    Abstract: Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: September 26, 2017
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, CASE WESTERN RESERVE UNIVERSITY
    Inventors: Tor C. Savidge, Jonathan Stamler
  • Patent number: 9657065
    Abstract: The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: May 23, 2017
    Assignee: Kuros Biosciences AG
    Inventors: Susanne Richter, Simon Topell
  • Patent number: 9631188
    Abstract: Human cystathionine ?-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine ?-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine ?-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: April 25, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Jan P. Kraus
  • Patent number: 9421203
    Abstract: The invention provides methods for overriding cell cycle arrest in a tumor cell, which comprise inducing DNA damage in the cell, and contacting the cell with an amount of bosutinib or a bosutinib isomer effective to inhibit one or more kinase constituents of a DNA damage checkpoint pathway. The invention also provides novel bosutinib isomers, as well as compositions of the novel isomers and the bosutinib isomer 3,5-dichloro-4-methoxyaniline.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 23, 2016
    Assignee: Institute for Cancer Research
    Inventors: Timothy Yen, Neil Beeharry
  • Patent number: 9321993
    Abstract: The present disclosure provides cell culture medium comprising trimethylamine N-oxide (TMAO). Progenitor cells cultured with such medium can form connective tissue with enhanced mechanical properties. Also provided are methods of forming connective tissue and methods of treatment for connective tissue defects.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: April 26, 2016
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Clark T. Hung, Grace D. O'Connell
  • Patent number: 9289474
    Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 22, 2016
    Assignee: VITACARE GMBH & CO. KG
    Inventors: Daniel Henry Wyrobnik, Isaac Harry Wyrobnik
  • Patent number: 9260484
    Abstract: A method of inhibiting a binding event between a target protein and a binding protein, comprising administering to a cell in vitro an effective amount of a non-naturally occurring bifunctional inhibitor molecule including (a) protein binding moiety, and (b) an effector region, wherein the protein binding moiety binds to a blocking protein, and wherein the effector region binds to the target protein in order to bind the target protein and the blocking protein and prevent access of the binding protein to the target protein. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 16, 2016
    Assignee: Ohio State Innovation Foundation
    Inventors: Roger Briesewitz, Dehua Pei, Xianghong Wu
  • Patent number: 9234210
    Abstract: The invention relates to newly identified selectable marker systems, cells for use in a selectable marker system, and methods for using the selectable marker systems.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: January 12, 2016
    Assignee: Intrexon CEU, Inc.
    Inventors: Imandokht Famili, Renata Usaite Black, Christophe H. Schilling
  • Patent number: 9220761
    Abstract: The invention features alginate and alginate lyase compositions and methods that are useful for the treatment of various conditions and diseases. The invention also provides kits and instructions for use.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: December 29, 2015
    Assignee: The John Hopkins University
    Inventors: Bradley P. Barnett, Philippe Gailloud
  • Patent number: 9149514
    Abstract: A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: October 6, 2015
    Assignee: MURAMI PHARMA, INC
    Inventor: Stefano Ferrari
  • Patent number: 9144601
    Abstract: Provided is a skeletal muscle regeneration promoter for a muscular disorder or myopathy comprising a chondroitinase as an active component, which skeletal muscle regeneration promoter enhances, when administered into a muscular fiber of a mammal with the muscular disorder or myopathy, the regeneration of such a muscular fiber. The above-mentioned chondroitinase degrades chondroitin sulfate that is present at the outer perimeter of the above-mentioned muscular fiber; and thereby inhibition of the regeneration of the muscular fiber by the above-mentioned chondroitin sulfate disappears, which makes it possible to enhance the regeneration and enlargement of such a muscular fiber.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: September 29, 2015
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Hiroshi Kitagawa, Tadahisa Mikami
  • Patent number: 9139876
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin such as unfractionated heparin and enoxaparin are described. In some instances, the mixtures are analyzed using high performance liquid chromatography (HPLC), e.g., reverse phase HPLC.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: September 22, 2015
    Assignee: MOMENTA PHARMACUETICALS, INC.
    Inventors: Zachary Shriver, Naveen Bhatnagar, Nur Sibel Gunay, Jennifer Ozug, Elaine Y. Sun
  • Patent number: 9040286
    Abstract: Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: May 26, 2015
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Craig Ceol, Yariv J. Houvras
  • Publication number: 20150139975
    Abstract: The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Christoph SCHMIDT, Paul N. BARLOW, Anna RICHARDS
  • Publication number: 20150139974
    Abstract: The invention relates to gene polymorphisms and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD and/or MPGNII. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of a individual which facilitate assessment of risk for developing such diseases.
    Type: Application
    Filed: September 22, 2014
    Publication date: May 21, 2015
    Inventor: Gregory S. Hageman
  • Publication number: 20150140072
    Abstract: Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Jeffry Dean Watkins, Alain Philippe Vasserot, Leslie Ann Greene, Ryan Andrew Adams, Kyle P. Chiang, Wei Zhang, Kristi Helen Piehl, Fei Hong, Alina He
  • Patent number: 9034320
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: May 19, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Patent number: 9034321
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: May 19, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Patent number: 9034319
    Abstract: A method of treating a cancer of the central nervous system in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent which reduces blood glutamate levels and enhances brain to blood glutamate efflux to thereby treat the cancer of the central nervous system in the subject.
    Type: Grant
    Filed: May 26, 2008
    Date of Patent: May 19, 2015
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Vivian I. Teichberg, Angela Ruban-Matuzani
  • Publication number: 20150132277
    Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 14, 2015
    Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
  • Publication number: 20150125438
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 5, 2013
    Publication date: May 7, 2015
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Bum Joon Kim, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Hwain Jang, Jung Soon Ha
  • Publication number: 20150125538
    Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.
    Type: Application
    Filed: October 27, 2014
    Publication date: May 7, 2015
    Applicant: OXTHERA INTELLECTUAL PROPERTY AB
    Inventors: Qingshan Li, Harmeet Sidhu
  • Publication number: 20150118228
    Abstract: A chimeric ErbB ligand binding molecule is disclosed along with its pharmaceutically acceptable salt forms. The molecule is a protein that as part of its sequence includes the sequence of SEQ ID NOS: 1, 2, or 3. The molecule can be fused to an IgGFc and especially IgGFc containing cysteine to serine changes in the hinge region. For example, the fusion can be to IgG 1Fc DNA sequences that encode the binding molecules are also contemplated as well as vectors containing such DNA sequences and hosts that contain such vectors. Pharmaceutical compositions are contemplated that contain the binding molecule along with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 30, 2015
    Inventor: Jason E. Hill
  • Publication number: 20150110766
    Abstract: A potent complement regulator is disclosed. The complement regulator comprises a complement regulatory region connected by a flexible linker to a multifunctional binding region that enables binding to C3b activation/inactivation products and/or oxidation end products, as well as to polyanionic surface markers on host cells. An embodiment of the invention utilizes factor H SCRs 1-4 as the complement regulatory region and factor H SCRs 19 and 20 as the multi-functional binding region, linked together by a poly-Gly linker at least 12 residues in length. Pharmaceutical compositions comprising the complement regulator and methods of using the complement regulator are also disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 23, 2015
    Applicant: UNIVERSITY ULM
    Inventors: John D. Lambris, Christoph Schmidt, Daniel Ricklin
  • Publication number: 20150110778
    Abstract: Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof.
    Type: Application
    Filed: September 6, 2012
    Publication date: April 23, 2015
    Applicant: Rutgers, the State University of New Jersery
    Inventors: Jianjie Ma, Noah Weisleder
  • Patent number: 9011844
    Abstract: Human cystathionine ?-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine ?-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologs are described. In addition, a method to express and purify recombinant human cystathionine ?-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 21, 2015
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventor: Jan P. Kraus